NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/30/2024
Back to search
Official data from USPTO
CELLIPONT BIOSERVICES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
CELLIPONT BIOSERVICES
ST13
US500000097251361Class
40, 42, 45
Filing
97251361
Registration
7375156
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
22
Latest update
04/30/2024
Trademark type
Word
Nice classes
40, 42, 45
Filing date
02/03/2022
Registration date
04/30/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/30/2024
Last transaction
04/30/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
02/14/2022
First use in commerce
02/14/2022
Drawing code
4
Owner type
03
Owner location
Poway, CA, US
Examiner
O'BRIEN, JENNIFER
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Performance Cell Manufacturing, Inc.
Representatives
Paul J. Kennedy TROUTMAN PEPPER HAMILTON SANDERS LLP
Technical classification
Nice Classes
Class 40Class 42Class 45
Vienna Codes
No Vienna codes available.
Goods and services
Class 40
Manufacturing services for others in the fields of gene therapymodified gene therapymodified cell therapycell therapytissue engineering and biopharmaceuticalscustom manufacture of pharmaceuticalschemotherapy drugs and antibiotic medicines by pharmaceutical compounders; manufacturing services for others in the fields of mammalian cell banksplasmidspurified mitochondriacell lysatesadenovirusadeno-associated virus (AAV)bacteriophagelentivirusretroviruses and other viruses found in mammalianscustom manufacture of pharmaceuticalschemotherapy drugs and antibiotic medicines by pharmaceutical compounders; manufacturing process consulting; Production in the nature of custom manufacture of cell lines for others using lentivirus technology; Production in the nature of custom manufacture of a recombinant or manipulated lentivirus; Production in the nature of custom manufacture of mitochondriacell lysatesadenovirusadeno-associated virus (AAV)bacteriophagelentivirusretroviruses and other viruses found in mammalians
Class 42
Research and development in the fields of gene therapymodified gene therapymodified cell therapycell therapytissue engineering and biopharmaceuticals; consulting services in the fields of research and development for gene therapymodified gene therapymodified cell therapycell therapytissue engineering and biopharmaceuticals; research and development of new products for others; process development services in the nature of research and development in the fields of gene therapymodified gene therapymodified cell therapycell therapytissue engineering and biopharmaceuticals; scientific research and technical research servicesresearch and development in the fields of assaying and purifying recombinant or manipulated lentivirus; Scientific and technical consulting servicesresearch and development in the fields of assayingpurifying mitochondriacell lysatesadenovirusadeno-associated virus (AAV)bacteriophagelentivirusretroviruses and other viruses found in mammalians; advisory services relating to research and development of gene therapy products and biopharmaceuticals; manufacturing support services for otherscGMP (Current Good Manufacturing Practice) quality control testing in support of biopharmaceutical development and manufacturing; quality control for others; quality management servicesquality evaluation and analysisquality assurancequality controlin the fields of gene therapymodified gene therapymodified cell therapycell therapytissue engineering and biopharmaceuticals; CDMO (Contract Development and Manufacturing Organization) servicespharmaceutical drug development services; material testing; product quality testing; scientific laboratory services; scientific research
Class 45
Providing regulatory compliance and regulatory compliance consultation and advisory services with respect to relevant state and federal law for organizations in the pharmaceuticalbiotechlife scienceother government-regulated industries
Publications
History of USPTO decisions and trademark events.
22 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/30/2024
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
03/29/2024
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/28/2024
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/04/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/04/2024
IUAF
USE AMENDMENT FILED
02/12/2024
EISU
TEAS STATEMENT OF USE RECEIVED
02/12/2024
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
08/29/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/04/2023
PUBO
PUBLISHED FOR OPPOSITION
07/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/14/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/26/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/24/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/24/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
11/28/2022
GNRT
NON-FINAL ACTION E-MAILED
11/28/2022
CNRT
NON-FINAL ACTION WRITTEN
11/28/2022
DOCK
ASSIGNED TO EXAMINER
11/16/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/08/2022
NWAP
NEW APPLICATION ENTERED
02/07/2022
Continuous trademark protection
Get notified about every new filing that threatens CELLIPONT BIOSERVICES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.